Latest news and press releases about HCW Biologics Inc. (HCWB): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases.
Price
| Price | $2.01 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.08 |
| EV / EBITDA | -1.60 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -142.16% |
| Return on Invested Capital | -39.28% |
| Return on Assets | -18.39% |
| Gross Margin | 95.91% |
| Operating Margin | -91.57% |
| Net Margin | -73.22% |
Related companies: ACXP · ADIL · APRE · APVO · BCDA · BCLI · CELZ
Explore sector: Healthcare · Biotechnology
More sections of HCWB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks